Science Summit at United Nations General Assembly (UNGA78)

Agenda (Version at 05h12 ET 13 Sept)

ONE HEALTH PLENARY
09h00
Declan Kirrane, ISC, Chair Science Summit UNGA78
Seema Kumar, CEO, CURE

09h10 Keynote 1
Prof Dr. Damalie Nakanjako
Principal of the College of Health Sciences – Director of the network ADAPT, Makerere University, Kampala, Uganda

09h25 Keynote 2
Dr Ghada Trotabas, Managing Director UK and Ireland, Siemens Healthineers

09h40 PANEL 1
What does an enabling policy and regulatory framework for One Health look like, and how can it be achieved in time for the post-SDG Agenda?

Moderator
Brian Wong, WHO European Observatory on Health Systems & Policies and FIND Diagnostics
Panel
Dr Rita Lawlor, ARC-NET : Centre for Applied Research on Cancer
Mr Brian O'Connor, Chair, ECHAlliance
Prof Dr. Uwe Truyen, Director of the Institute of Animal Hygiene and Veterinary Public Health – Co-Director of the network ADAPT, Faculty of Veterinary Medicine, Leipzig University, Leipzig, Germany
Josef
Prof Kurt Zatloukal, Medical University of Graz, Diagnostic and Research Center for Molecular Biomedicine

10h15 Keynote
Dr. Sanjeev Khosla, CSIR-Institute of Microbial Technology, India, Director (V)

10h30 PANEL 2
How can measures to achieve One Health be inclusive?
Moderator
Dr Magdalena Skipper
Panel
Dr Natasha Sunderji, Accenture
Dr Sharif Muhammad, ICESCO (V)
Dr Salome Charalambous, Implementation Research, The Aurum Institute Johannesburg, South Africa, Group Chief Science Officer – Director of the network TB Sequel


11h20 Break

11h30 Keynote 4
Dr Mosoka Fallah, Africa Center for Disease Control (V)

11h45 PANEL 3
Recommendations for the Summit of the Future

Moderator
Ms Rita Lawlor, ARC-Net, University of Verona
Panel
Dr Moses Aloba, Science for Africa
Dr Michael Makanga, EDCTP
Dr Marcel Tanner, Swiss Academies of Arts and Sciences and EDCTP, President (V)
Dr Litha Magingxa, President and CEO, Agricultural research technologies for climate resilience (V)

12h30 Keynote 5: Reflections
Dr Irene Norstedt, Director, People Directorate, DG Research and Innovation, European Commission
12h40 Concluding Remarks:
Dr. Anna Stewart Ibarra

Agenda (Version at 05h12 ET 13 Sept)

ONE HEALTH PLENARY
09h00
Declan Kirrane, ISC, Chair Science Summit UNGA78
Seema Kumar, CEO, CURE

09h10 Keynote 1
Prof Dr. Damalie Nakanjako
Principal of the College of Health Sciences – Director of the network ADAPT, Makerere University, Kampala, Uganda

09h25 Keynote 2
Dr Ghada Trotabas, Managing Director UK and Ireland, Siemens Healthineers

09h40 PANEL 1
What does an enabling policy and regulatory framework for One Health look like, and how can it be achieved in time for the post-SDG Agenda?

Moderator
Prof Kurt Zatloukal, Medical University of Graz, Diagnostic and Research Center for Molecular Biomedicine

Panel
Dr Rita Lawlor, ARC-NET : Centre for Applied Research on Cancer
Mr Brian O'Connor, Chair, ECHAlliance
Prof Dr. Uwe Truyen, Director of the Institute of Animal Hygiene and Veterinary Public Health – Co-Director of the network ADAPT, Faculty of Veterinary Medicine, Leipzig University, Leipzig, Germany
Josef

10h15 Keynote
Dr. Sanjeev Khosla, CSIR-Institute of Microbial Technology, India, Director (V)

10h30 PANEL 2
How can measures to achieve One Health be inclusive?

Moderator
Dr Magdalena Skipper

Panel
Dr Natasha Sunderji, Accenture
Dr Sharif Muhammad, ICESCO (V)
Dr Salome Charalambous, Implementation Research, The Aurum Institute Johannesburg, South Africa, Group Chief Science Officer – Director of the network TB Sequel
Dr Brian Wong I-DAIR

11h20 Break

11h30 Keynote 4
Dr Mosoka Fallah, Africa Center for Disease Control (V)

11h45 PANEL 3
Recommendations for the Summit of the Future

Moderator
Mrs Rita Lawlor, ARC-Net, University of Verona

Panel
Dr Moses Aloba, Science for Africa
Dr Michael Makanga, EDCTP
Dr Marcel Tanner, Swiss Academies of Arts and Sciences and EDCTP, President (V)
Dr Litha Magingxa, President and CEO, Agricultural research technologies for climate resilience (V)

12h30 Keynote 5: Reflections
Dr Irene Norstedt, Director, People Directorate, DG Research and Innovation, European Commission

12h40 Concluding Remarks:
Dr Anna Stewart Ibarra

VENUE LOCATION
CURE, 345 Park Ave South, New York.
Pay attention to the S-O-U-T-H part, otherwise you will be very lost.

Pandemic Preparedness: Defining the UN-level strategy for the Summit of the Future 2024 with the National Research Foundation, South Africa

Agenda (at 04h28EDT, Thursday 14 September 2023)

08h25 Welcome
Declan Kirrane, Chairman, Science Summit at UNGA78
Seema Kumar, CEO, CURE


08h30 PANEL 1 -- Scene Setting
Petra Jantzer, Life Sciences Global Lead, Accenture (Mod)
Marc Carrel-Billiard, Technology Innovation Global Lead, Accenture
Fulufhelo Nelwamondo, CEO, National Research Foundation, South Africa (V)
Johan Aubert, Chief Digital Officer, Research and Innovation L'Oreal
Hillel Lehmann, Vice President, Head of Transformation & Long-term Strategy, Nestlé Health Sciences
Rob Goodwin, Senior Vice President, Clinical Development and Operations, Pfizer


10h00 PANEL 2 Global Challenges Response
Kurt Zatloukal, Medical University Graz, Austria (Mod)
Magdalena Skipper, Editor-in-Chief, Nature, UK
Seema Kumar, CURE by Deerfield, USA
Osamu Kunii, Global Health Innovative Technology Fund, Japan (V)
Vinay K. Nandicoori Director, CSIR-Centre for Cellular and Molecular Biology, Hyderabad, Telangana, India

11h00 Keynote: Aunkh Chabalala, National Director of the Indigenous Knowledge-Based Technology Innovation Unit Dept of Science and Innovation, South Africa

11h15 Break

11h30 PANEL 3 100 Days Mission Panel: The Science of Access to Medical Countermeasures for Pandemic Preparedness

Moderator: Lidia Borrell-Damian, Secretary-General, ScienceEurope

As shown during the response to COVID-19, the faster we can develop safe, effective and affordable diagnostics, therapeutics and vaccines (DTVs) for an escalating infectious disease, the more lives we can save.
The goal of the 100 Days Mission is to prepare as much as possible so that within the first 100 days that a pandemic threat is identified, the following interventions can be made available, safe, effective, and affordable:

Accurate and approved rapid point-of-care diagnostic tests
An initial regimen of therapeutics
Vaccines ready to be produced at scale for global deployment

In 2021, G7 and G20 Leaders welcomed the 100 Days Mission, building on the collaborative scientific efforts which led to the development of DTVs for COVID-19. The 1st 100 Days Mission report was authored by scientific, governmental and industry experts drawn from within and beyond the G7. It proposed 25 recommendations to harness scientific innovation and strengthen public and private collaboration that will reduce the time from discovery to deployment of DTVs within 100 days of the next pandemic threat.

Panel Concept: This session will discuss the following:
Background to the 100 Days Mission, its connection to the wider SDG agenda, and its value proposition for a safer world through scientific innovation to condense timelines and equitable access to countermeasures.
The learnings from COVID-19 and the policy solutions that underpin the 100 Days Mission
How upcoming political processes, including UNHLM on PPR and INB/IHR processes, will support this work, and how other opportunities, including a new MCM network and G7 and G20 presidencies, can make the 100 Days Mission a reality

11h30 - 11h35 Welcome: Dr Victor Dzau (President of the National Academy of Medicine and STEG co-chair) and Dr Rick A Bright (Former Director of BARDA, FIND board member)

11h35 - 11h45 Opening Remarks: Introduction to the 100 Days Mission and Science and Technology Expert Group (STEG) by Dr Victor Dzau (President of the National Academy of Medicine and STEG co-chair)


11h45 - 12h10 Panellist Remarks: 5-minute interventions from
Dr Nicole Lurie (US Director, CEPI), Shingai Machingaidze (Ag. Chief Science Officer, Africa CDC),
Dr Rick A Bright (Former Director of BARDA, FIND Board Member)
and
Dr Ruxandra Draghia-Akli (V) (Global Head, Johnson & Johnson Global Public Health R&D), on the global lessons captured from COVID-19 for pandemic preparedness R&D and the recommendations for ensuring countermeasures can deliver equity and innovation, with sustainable financial and political will.

12h10-12h45 Moderated Q&A between attendees and panellists

12h45-12h55 Closing Remarks: Global political opportunities for implementing the recommendations by Dr Mariângela Simão (Former WHO Assistant Director-General for Drug Access Vaccines and Pharmaceuticals)

12h55-13h00 Goodbyes: Dr Victor Dzau (President of the National Academy of Medicine and STEG co-chair) and Dr Rick A Bright (Former Director of BARDA, FIND Board Member)

13h00 Lunch (by Invitation)

14h00 Keynote: Policy Responses
Irene Norstedt, European Commission, Belgium:
Petra Jantzer Global Life Sciences Lead & Senior Managing Director, Accenture


14h45 PANEL 4 -- Harnessing Indigenous knowledge systems to combat diseases of poverty
Magdalena Skipper, Editor-in-Chief, Nature, UK Moderator
Mosoka Fallah, Founder and Chief Executive Officer (CEO), Refuge Place International
Thomas John, Chief Strategy Officer, Landcent
Michael Makanga, European Developing Countries Clinical Trails Programme
Aunkh Chabalala, National Director of the Indigenous Knowledge-Based Technology Innovation Unit, Dept of Science and Innovation. South Africa
Peter Atadja, Chief Scientific Advisor, Landcent

15h45 PANEL 5 -- Building Communities of Practice for Interpandemic Sciences in Africa – Science for Africa Foundation
Moses Alobo, Science for Africa Foundation
Thomas Kariuki, CEO, Science for Africa Foundation, Kenya
Jinal Bhiman Global Immunology and Immune Sequencing for Epidemic Response South Africa (GIISER-SA), NICD
Christian Happi, Redeemers University, Nigeria

16h30 Recommendation for the Summit of the Future and Concluding Panel
Triona McCormack, UCD, Ireland - Moderator:
Alison Derbenwick Miller, Oracle
Brian O'Connor, Chairman, ECHAlliance
Carlos Americo Pacheco, FAPESP
Josef Glößl, BOKU, Austria

VENUE LOCATION
CURE, 345 Park Ave South, New York.
Pay attention to the S-O-U-T-H part, otherwise you will be very lost.

Pandemic Preparedness: Defining the UN-level strategy for the Summit of the Future 2024 with the National Research Foundation, South Africa

Agenda (at 04h28EDT, Thursday 14 September 2023)

08h25 Welcome
Declan Kirrane, Chairman, Science Summit at UNGA78
Seema Kumar, CEO, CURE


08h30 PANEL 1 -- Scene Setting
Petra Jantzer, Life Sciences Global Lead, Accenture (Mod)
Marc Carrel-Billiard, Technology Innovation Global Lead, Accenture
Fulufhelo Nelwamondo, CEO, National Research Foundation, South Africa (V)
Johan Aubert, Chief Digital Officer, Research and Innovation L'Oreal
Hillel Lehmann, Vice President, Head of Transformation & Long-term Strategy, Nestlé Health Sciences
Rob Goodwin, Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer


10h00 PANEL 2 Global Challenges Response
Kurt Zatloukal, Medical University Graz, Austria (Mod)
Magdalena Skipper, Editor-in-Chief, Nature, UK
Seema Kumar, CURE by Deerfield, USA
Osamu Kunii, Global Health Innovative Technology Fund, Japan (V)

11h00 Keynote: Aunkh Chabalala, National Director of the Indigenous Knowledge-Based Technology Innovation Unit Dept of Science and Innovation, South Africa

11h15 Break

11h30 PANEL 3 100 Days Mission Panel: The Science of Access to Medical Countermeasures for Pandemic Preparedness

Moderator: Lidia Borrell-Damian, Secretary-General, ScienceEurope

As shown during the response to COVID-19, the faster we can develop safe, effective and affordable diagnostics, therapeutics and vaccines (DTVs) for an escalating infectious disease, the more lives we can save.
The goal of the 100 Days Mission is to prepare as much as possible so that within the first 100 days that a pandemic threat is identified, the following interventions can be made available, safe, effective, and affordable:

Accurate and approved rapid point-of-care diagnostic tests
An initial regimen of therapeutics
Vaccines ready to be produced at scale for global deployment

In 2021, G7 and G20 Leaders welcomed the 100 Days Mission, building on the collaborative scientific efforts which led to the development of DTVs for COVID-19. The 1st 100 Days Mission report was authored by scientific, governmental and industry experts drawn from within and beyond the G7. It proposed 25 recommendations to harness scientific innovation and strengthen public and private collaboration that will reduce the time from discovery to deployment of DTVs within 100 days of the next pandemic threat.

Panel Concept: This session will discuss the following:
Background to the 100 Days Mission, its connection to the wider SDG agenda, and its value proposition for a safer world through scientific innovation to condense timelines and equitable access to countermeasures.
The learnings from COVID-19 and the policy solutions that underpin the 100 Days Mission
How upcoming political processes, including UNHLM on PPR and INB/IHR processes, will support this work, and how other opportunities, including a new MCM network and G7 and G20 presidencies, can make the 100 Days Mission a reality

11h30 - 11h35 Welcome: Dr Victor Dzau (President of the National Academy of Medicine and STEG co-chair) and Dr Rick A Bright (Former Director of BARDA, FIND board member)

11h35 - 11h45 Opening Remarks: Introduction to the 100 Days Mission and Science and Technology Expert Group (STEG) by Dr Victor Dzau (President of the National Academy of Medicine and STEG co-chair)


11h45 - 12h10 Panellist Remarks: 5-minute interventions from
Dr Nicole Lurie (US Director, CEPI), Shingai Machingaidze (Ag. Chief Science Officer, Africa CDC),
Dr Rick A Bright (Former Director of BARDA, FIND Board Member)
and
Dr Ruxandra Draghia-Akli (V) (Global Head, Johnson & Johnson Global Public Health R&D), on the global lessons captured from COVID-19 for pandemic preparedness R&D and the recommendations for ensuring countermeasures can deliver equity and innovation, with sustainable financial and political will.

12h10-12h45 Moderated Q&A between attendees and panellists

12h45-12h55 Closing Remarks: Global political opportunities for implementing the recommendations by Dr Mariângela Simão (Former WHO Assistant Director-General for Drug Access Vaccines and Pharmaceuticals)

12h55-13h00 Goodbyes: Dr Victor Dzau (President of the National Academy of Medicine and STEG co-chair) and Dr Rick A Bright (Former Director of BARDA, FIND Board Member)

13h00 Lunch (by Invitation)

14h00 Keynote: Policy Responses
Irene Norstedt, European Commission, Belgium:


14h45 PANEL 4 -- Harnessing Indigenous knowledge systems to combat diseases of poverty
Magdalena Skipper, Editor-in-Chief, Nature, UK Moderator
Mosoka Fallah, Founder and Chief Executive Officer (CEO), Refuge Place International
Thomas John, Landcent
Michael Makanga, European Developing Countries Clinical Trails Programme
Aunkh Chabalala, National Director of the Indigenous Knowledge-Based Technology Innovation Unit, Dept of Science and Innovation. South Africa
Peter Atadja, Chief Scientific Advisor, Landcent

15h45 PANEL 5 -- Building Communities of Practice for Interpandemic Sciences in Africa – Science for Africa Foundation
Thomas Kariuki, CEO, Science for Africa Foundation, Kenya
Jinal Bhiman Global Immunology and Immune Sequencing for Epidemic Response South Africa (GIISER-SA), NICD
Christian Happi, Redeemers University, Nigeria

16h30 Recommendation for the Summit of the Future and Concluding Panel
Triona McCormack, UCD, Ireland - Moderator:
Alison Derbenwick Miller, Oracle, USA
Carlos Americo Pacheco, FAPESP
Josef Glößl, BOKU, Austria

Pandemic preparedness is vital for protecting public health, maintaining economic stability, ensuring global health security, strengthening healthcare systems, fostering scientific advancements, reducing risks, and engaging communities. By investing in preparedness, we can minimise the impact of pandemics and build a more resilient world as a key pillar of SDG 3.

The world's response to the COVID-19 pandemic revealed significant shortcomings in global public health emergency preparedness. Particularly in Africa, access to vaccines was unavailable, highlighting the need for better pandemic prediction and prevention. Vaccine hesitancy underscored the importance of engaging all sectors of society. Africa's experience with HIV/AIDS and TB epidemics provided valuable expertise and infrastructure for the COVID-19 response. However, funding shortages and the far-reaching impact of COVID-19 necessitate the establishment of a multi-sectoral entity to strengthen disease control stra

Introduction and aims

We represent a group of researchers and clinical practitioners working with Universities and Foundations in the United States to partner on health and education research in local communities in East Africa (Kenya and Uganda). Our work spans rural and urban settings for understanding the contributions local communities and indigenous wisdom can offer to the science of health-seeking behavior and human flourishing, including the context of education. We shall share the challenges we face in collaborating remotely and in-person on complex problems related to neurology, public health, and infectious disease. Those challenges include IRB approval policies across countries and the need to attend to repeatable scientific data and evidence provided in open-source venues, per requirements issued by research funding bodies. Who owns the data and how the data can be equitably sourced, accessed, and distributed, remains a crucial problem of our work. Our hypothesis is that by sharing our own challenges in navigating international science policy frameworks, we may work with other delegates to ensure more significant equity and inclusion for marginalized voices in East Africa, including the Batwa, an historically marginalized set of communities' long-denied human rights.

Abstract

We use mixed methods for our human subject research in neurology, infectious disease, and education practices. In one study represented here, the researchers hypothesize that kinship relations, including ancestral and spiritual actors, strongly influence health-seeking behavior and thus must be studied qualitatively and quantitatively to ensure sound principles guide future health interventions. The proposed study has two complementary aims.

The first is empirical:
(1) To determine how social networks impact treatment-seeking for a group of 50 participants in Uganda. To do this, they will collect data on patient behavior and social connections using a network mapping and survey tool called PERSNET. The second aim is theoretical,
(2) To develop from the data a theory of the benefits and dangers of viewing humans as “porous” or readily influenced by outside forces and actors in the context of healthcare.

The applied potential of this theory is to support the design of culturally and contextually appropriate brain health interventions. This study is motivated by recognising the shortcomings of the disease-centric model of medicine, which prioritizes technological and biomedical solutions to physical health while failing to recognize the influence of the social or cultural environment on well-being. Referencing Charles Taylor’s conceptualization of the “buffered” and “porous” models of personhood, the researchers propose that the current disease model of health care must evolve in a way that recognizes the porosity of human beings and the interconnectedness of individuals to their broader social context. This project seeks to contribute to this aim.

An interdisciplinary team leads the project from the Human Network Initiative, which includes a philosopher, neuroscientist and theologian, building on existing research partnerships in Uganda. The Human Network Initiative is located in the Neurology Department of Harvard Medical School / Brigham and Women’s Hospital. It seeks to explore the manifold and massive ways that interpersonal community, or its lack of presence, affect brain health and general flourishing.

Other represented researchers and clinical practitioners include those specializing in randomized control trials in Kenya and Uganda, as well as infectious disease and women's health in the rural rainforest region of southwestern Uganda.

Expected outcomes

The outcomes of the research are many:
(1) open source publications;
(2) international conferences;
(3) short documentary films;
(4) up-skilling of local community-based research partners.

Overall, our work will shape international science policy by including neglected communities and side-lined traditions of wisdom that inform the daily lives of millions of people in East Africa and the United States. Our international partnerships can ensure that more voices can shape science policy, especially in matters of data governance and ownership with respect to public health.

The SPRINT projects (sprint-h2020.eu) is related to the target of the European Farm to Fork Strategy: a 50% reduction in chemical pesticide use and risk by 50% by 2030. SPRINT addresses the urgent need to assess the actual presence of  pesticide residues in terrestrial and aquatic ecosystems, indoor dust and human matrices across Europe, covering the main cropping systems. Furthermore, we address the risk of pesticide mixtures for ecosystem and human health.
SPRINT is the first European wide effort to monitor real pesticide application patterns (Mark et al. 2023) and the resulting distribution of pesticide residues across all main European cropping systems. Therefore, we monitored during the growing season of 2021 in 10 European case study sites. We took about 600 samples across environmental matrices - soil, plant, surface water, sediment, air and indoor dust and blood, urine and feces samples from 670 persons.
We assess residue distribution connected to different farming systems (organic, integrated), taking the fact into consideration that synthetic pesticides are not applied in organic farming systems, but that they may be still present due to applications in the past or by deposition due to off-site transport.
SPRINT focuses on more than 200 active substances of synthetic pesticides and their metabolites from group 2 (approved), group 3 (candidates of substitution) and group 4 (banned at EU level) as categorized by the EC (2020).
We link the residue distribution in the different matrices to the hazardous properties of the residues (EFSA conclusions, PPDB database) for ecosystem and human health and introduce a Risk Indicator as a base for the 50% risk reduction target of the Farm to Fork strategy.
Based on field results we test the mixtures’ impact on the aquatic and terrestrial ecosystem conducting innovative ecotoxicological tests with sensitive indicators. Furthermore, we assess human health effects conducting in vitro tests with colon ilium and long organoids.
The SPRINT session provides highly important knowledge needed to solve the urgent questions on how to reduce pesticide risk as a base for a transition to sustainable agriculture. We provide data and a new risk indicator that can be included in new regulations.


Session title: Pesticide residues in the ecosystem and humans across Europe and Argentina: linking SPRINT field data to health risks
Duration: 9:30 am to 12:30 pm
  Introduction to the SPRINT project by Violette Geissen
 Time: 9:30 to 9:35
 1.   Title: Pesticide residues with hazard classifications omnipresent in the European environment and farmer residences
       Speaker: Violette Geissen, Wageningen University, NL
       Time: 9:35 to 9:50 am


 2. Title: How is exposure to pesticides affecting ecosystem, plant, animal and human health? An assessment based on SPRINT field campaign across Europe and Argentina
 Speaker: Abdallah Alaoui, University of Bern, CH
 Time: 9:50 to 10:05 am


 3. Title: Linking pesticide residues in indoor dust to human exposure of residents living close to conventional and organic farming.
 Speaker: Daniel M. Figueiredo, Utrecht University, NL
 Time: 10:05 to 10:20 am


 4. Title: Pesticides in human urine and feces: human biomonitoring to assess internal exposure to pesticides
 Speaker: Hans Mol, Wageningen Research, NL
 Time: 10:20 to 10:35 am


 5. Title: Pesticides and gut health – some pesticides influence gut microbiome composition and negatively impact cells lining the gut
 Speaker: Maaike Gerritse, Wageningen University, NL
 Time: 10:35 to 10:50 am


Coffee Break ------Coffee Break ------Coffee Break --- (10 minutes)


6. Title: Pesticide Exposure by Air at two Agricultural Sites in Europe
 Speaker: Freya Debler, Helmholtz Zentrum Heroen, D
 Time: 11:00 to 11:15 am


 7. Title: Pesticide transport by wind in sediment originating from agricultural fields
 Speaker: Dirk Goossens, Wageningen University, NL and KU Leuven, BE
 Time: 11:15 to 11:30 am


 8. Title: Risks and costs related to pesticide applications on a global scale
 Speaker: Peter Fantke, Technical University of Denmark, DK
 Time: 11:30 to 11:45 am


 9. Title: Risk of pesticide mixtures on the terrestrial ecosystem –effects on earthworms, springtails, and bees
 Speaker: Kayode Jegede, Wageningen University, NL
 Time: 11:45 to 12:00 pm


 10. Title: Impacts of realistic pesticide mixtures on freshwater ecosystems
 Speaker: Nelson Abrantes, University of Aveiro, PT
 Time: 12:00 to 12:15 pm


 11.  Final discussion and recommendations for the future
 Speaker: Violette Geissen
 Time: 12:15 to 12:30 pm


https://us02web.zoom.us/rec/share/6FaOr1kacwWKvohNNfjNgzz5g635P3DdAz1UZ1DxEwA-X34QLDCmoTk8xRCuM3Ew.X6PUzuwaYiFZhRdW